BioMimetic Therapeutics, Inc. is a biotechnology company engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The Company's Augment platform of product and product candidates include an engineered version of recombinant human platelet-derived growth factor BB (rhPDGF-BB), one of the wound healing and tissue repair stimulators in the body. Its platform regenerative technology for promoting tissue healing and regeneration combines rhPDGF-BB with tissue specific matrices, when appropriate. The matrices are engineered or natural scaffold materials, such as Beta Tri-Calcium Phosphate. The Company's product candidates include Augment Bone Graft (Augment), Augmen Injectable Bone Graft (Augment Injectable) and Augment Rotator Cuff Graft (Augment Rotator Cuff Graft). In March 2013, Wright Medical Group Inc completed acquisition of BioMimetic Therapeutics, Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:BMTI
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for BioMimetic Therapeutics (NASDAQ:BMTI)
What is BioMimetic Therapeutics' stock symbol?
BioMimetic Therapeutics trades on the NASDAQ under the ticker symbol "BMTI."
Who are some of BioMimetic Therapeutics' key competitors?
Some companies that are related to BioMimetic Therapeutics include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), Catalent (CTLT), NMC Health PLC (NMC), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI), Hikma Pharmaceuticals Plc (HIK) and WuXi PharmaTech (Cayman) (WX).
How do I buy BioMimetic Therapeutics stock?
Shares of BioMimetic Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioMimetic Therapeutics' stock price today?
MarketBeat Community Rating for BioMimetic Therapeutics (NASDAQ BMTI)MarketBeat's community ratings are surveys of what our community members think about BioMimetic Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BioMimetic Therapeutics stock can currently be purchased for approximately $9.49.
Consensus Ratings for BioMimetic Therapeutics (NASDAQ:BMTI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for BioMimetic Therapeutics (NASDAQ:BMTI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for BioMimetic Therapeutics (NASDAQ:BMTI)Earnings History by Quarter for BioMimetic Therapeutics (NASDAQ BMTI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for BioMimetic Therapeutics (NASDAQ:BMTI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for BioMimetic Therapeutics (NASDAQ:BMTI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BioMimetic Therapeutics (NASDAQ:BMTI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for BioMimetic Therapeutics (NASDAQ:BMTI)
Latest Headlines for BioMimetic Therapeutics (NASDAQ:BMTI)
No headlines for this company have been tracked by MarketBeat.com
BioMimetic Therapeutics (BMTI) Chart for Tuesday, July, 25, 2017